NZ628993A - Pharmaceutical formulations comprising ccr3 antagonists - Google Patents

Pharmaceutical formulations comprising ccr3 antagonists

Info

Publication number
NZ628993A
NZ628993A NZ628993A NZ62899313A NZ628993A NZ 628993 A NZ628993 A NZ 628993A NZ 628993 A NZ628993 A NZ 628993A NZ 62899313 A NZ62899313 A NZ 62899313A NZ 628993 A NZ628993 A NZ 628993A
Authority
NZ
New Zealand
Prior art keywords
diluent
alkyl
disintegrant
lubricant
binder
Prior art date
Application number
NZ628993A
Other languages
English (en)
Inventor
Alfred Fetscher
Jochen Matthias Scher
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49292482&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ628993(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of NZ628993A publication Critical patent/NZ628993A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Inorganic Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NZ628993A 2012-04-04 2013-04-02 Pharmaceutical formulations comprising ccr3 antagonists NZ628993A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12163078 2012-04-04
PCT/EP2013/056867 WO2013149987A1 (en) 2012-04-04 2013-04-02 Pharmaceutical formulations comprising ccr3 antagonists

Publications (1)

Publication Number Publication Date
NZ628993A true NZ628993A (en) 2016-08-26

Family

ID=49292482

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ628993A NZ628993A (en) 2012-04-04 2013-04-02 Pharmaceutical formulations comprising ccr3 antagonists

Country Status (31)

Country Link
US (3) US10213421B2 (enExample)
EP (3) EP3524230B1 (enExample)
JP (4) JP6320990B2 (enExample)
KR (2) KR102338465B1 (enExample)
CN (1) CN104203213A (enExample)
AR (1) AR090596A1 (enExample)
AU (1) AU2013245028B2 (enExample)
BR (1) BR112014024479A8 (enExample)
CA (1) CA2869058C (enExample)
CL (1) CL2014002524A1 (enExample)
CY (1) CY1121137T1 (enExample)
DK (2) DK3524230T3 (enExample)
EA (1) EA027627B1 (enExample)
ES (3) ES3044310T3 (enExample)
HR (1) HRP20190069T1 (enExample)
HU (2) HUE056943T2 (enExample)
IL (1) IL234299A (enExample)
IN (1) IN2014DN07082A (enExample)
LT (1) LT2833864T (enExample)
MX (1) MX358307B (enExample)
NZ (1) NZ628993A (enExample)
PH (1) PH12014502241A1 (enExample)
PL (2) PL2833864T3 (enExample)
PT (2) PT2833864T (enExample)
RS (1) RS58360B1 (enExample)
SI (1) SI2833864T1 (enExample)
SM (1) SMT201900121T1 (enExample)
TR (1) TR201821285T4 (enExample)
TW (1) TW201400115A (enExample)
UY (1) UY34730A (enExample)
WO (1) WO2013149987A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8278302B2 (en) 2009-04-08 2012-10-02 Boehringer Ingelheim International Gmbh Substituted piperidines as CCR3 antagonists
UA109290C2 (uk) 2010-10-07 2015-08-10 Спільні кристали і солі інгібіторів ccr3
AR090566A1 (es) 2012-04-02 2014-11-19 Boehringer Ingelheim Int Proceso para la produccion de inhibidores de crr
US20130261153A1 (en) * 2012-04-03 2013-10-03 Boehringer Ingelheim International Gmbh Use of ccr3-inhibitors
US10213421B2 (en) * 2012-04-04 2019-02-26 Alkahest, Inc. Pharmaceutical formulations comprising CCR3 antagonists
US11382907B2 (en) * 2017-04-05 2022-07-12 Alkahest, Inc. Methods and compositions for treating aging-associated impairments using CCR3-inhibitors
SG11201909207VA (en) 2017-04-05 2019-11-28 Alkahest Inc Methods and compositions for treating retina-associated disease using ccr3-inhibitors
WO2019075351A1 (en) * 2017-10-13 2019-04-18 Alkahest, Inc. METHODS AND COMPOSITIONS FOR TREATING PRURIT, XEROSIS AND ASSOCIATED DISEASE USING CCR3 INHIBITORS
MY198220A (en) 2018-05-15 2023-08-14 Alkahest Inc Treatment Of Aging-Associated Disease With Modulators Of Leukotriene A4 Hydrolase
AU2019346456A1 (en) * 2018-09-26 2021-04-15 Alkahest, Inc. Methods and compositions for treating aging-associated impairments using CCR3-inhibitors
KR20230056017A (ko) 2020-08-27 2023-04-26 에이지씨 가부시키가이샤 무알칼리 유리 및 유리판
WO2023076679A1 (en) 2021-11-01 2023-05-04 Alkahest, Inc. Benzodioxane modulators of leukotriene a4 hydrolase (lta4h) for prevention and treatment of aging-associated diseases

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7907121L (sv) 1979-08-27 1981-02-28 Astra Laekemedel Ab Ftalimidinderivat
US4992277A (en) 1989-08-25 1991-02-12 Schering Corporation Immediate release diltiazem formulation
JP2807577B2 (ja) 1990-06-15 1998-10-08 エーザイ株式会社 環状アミド誘導体
IL116539A (en) * 1995-01-06 2002-02-10 Noven Pharma Preparations given through the skin of unstable anti-acid drugs
WO1998050019A1 (en) * 1997-05-09 1998-11-12 Sage Pharmaceuticals, Inc. Stable oral pharmaceutical dosage forms
CA2318088A1 (en) 1998-01-21 1999-07-29 Yoshisuke Nakasato Chemokine receptor antagonists and methods of use therefor
JP2002501898A (ja) 1998-02-02 2002-01-22 メルク エンド カムパニー インコーポレーテッド ケモカイン受容体活性の環状アミン調節剤
US6140349A (en) 1998-02-02 2000-10-31 Merck & Co., Inc. Cyclic amine modulators of chemokine receptor activity
SE9802973D0 (sv) 1998-09-03 1998-09-03 Astra Ab Immediate release tablet
EP2305257A1 (en) * 2002-07-08 2011-04-06 ChemGenex Pharmaceuticals, Inc. Amonafide salts and compositions comprising same
JP4792392B2 (ja) 2003-09-11 2011-10-12 コーナーストーン セラピューティクス インコーポレイテッド Ｈｍｇｂ１に対するモノクローナル抗体
WO2005040129A2 (en) 2003-10-24 2005-05-06 F. Hoffmann-La Roche Ag Ccr3 receptor antagonists
NZ547314A (en) 2003-11-17 2010-02-26 Boehringer Ingelheim Int Novel piperidine-substituted indoles- or hetero-derivatives thereof and their use as modulators of chemokine receptor (CCR-3)
ATE428422T1 (de) 2004-02-05 2009-05-15 Schering Corp Piperidin-derivate als ccr3-antagonisten
JP2006137718A (ja) 2004-11-12 2006-06-01 Astellas Pharma Inc インドール若しくはインダゾール誘導体
US8030003B2 (en) 2004-12-07 2011-10-04 Children's Hospital Medical Center Diagnosis of eosinophilic esophagitis based on presence of an elevated level of eotaxin-3
DOP2006000051A (es) 2005-02-24 2006-08-31 Lilly Co Eli Inhibidores de vegf-r2 y métodos
JP3701964B1 (ja) 2005-03-08 2005-10-05 アステラス製薬株式会社 キヌクリジン誘導体の新規な塩
EP1994019B1 (en) 2005-04-30 2011-11-02 Boehringer Ingelheim International GmbH Novel piperidin - substituted indoles and their use as ccr-3 modulators
NL2000323C2 (nl) * 2005-12-20 2007-11-20 Pfizer Ltd Pyrimidine-derivaten.
US20090124636A1 (en) 2006-04-12 2009-05-14 Pfizer Inc. Chemical compounds
US8148403B2 (en) 2006-10-27 2012-04-03 Boehringer Ingelheim International Gmbh Substituted piperidyl-propane-thiols
US8153660B2 (en) 2006-10-27 2012-04-10 Boehringer Ingelheim International Gmbh Piperidyl-propane-thiol CCR3 modulators
GB0701992D0 (en) 2007-02-02 2007-03-14 7Tm Pharma As Grehlin Receptor Modulators
US8008092B2 (en) 2007-10-09 2011-08-30 University Of Kentucky Research Foundation CCR3 inhibition for ocular angiogenesis and macular degeneration
EP2222649A2 (en) 2007-10-24 2010-09-01 Generics (UK) Limited Novel crystalline forms
TW201000446A (en) 2008-05-30 2010-01-01 Astrazeneca Ab New compounds useful in pain therapy
WO2010052727A1 (en) * 2008-11-04 2010-05-14 Ideal Cures Private Limited High performance film coating compositions
US8278302B2 (en) * 2009-04-08 2012-10-02 Boehringer Ingelheim International Gmbh Substituted piperidines as CCR3 antagonists
KR20120070629A (ko) * 2009-04-22 2012-06-29 액시킨 파마수티컬스 인코포레이티드 2,5-이치환 아릴설폰아마이드 ｃｃｒ3 길항제
EP2749554B1 (en) 2009-04-22 2017-12-20 SMA Therapeutics, Inc. 2,5-disubstituted arylsulfonamide CCR3 antagonists
WO2011083402A2 (en) * 2010-01-11 2011-07-14 Muneera Mohamed Shafee Immediate release compositions of acid labile drugs
UA109290C2 (uk) 2010-10-07 2015-08-10 Спільні кристали і солі інгібіторів ccr3
AR090566A1 (es) 2012-04-02 2014-11-19 Boehringer Ingelheim Int Proceso para la produccion de inhibidores de crr
US20130261153A1 (en) 2012-04-03 2013-10-03 Boehringer Ingelheim International Gmbh Use of ccr3-inhibitors
US10213421B2 (en) 2012-04-04 2019-02-26 Alkahest, Inc. Pharmaceutical formulations comprising CCR3 antagonists

Also Published As

Publication number Publication date
CA2869058C (en) 2020-07-07
AU2013245028A1 (en) 2014-09-11
EP2833864B1 (en) 2018-12-19
US20130266646A1 (en) 2013-10-10
PT3524230T (pt) 2021-11-12
JP2020143080A (ja) 2020-09-10
KR102338465B1 (ko) 2021-12-14
JP6320990B2 (ja) 2018-05-09
KR20140140064A (ko) 2014-12-08
IL234299A (en) 2017-07-31
KR102138709B1 (ko) 2020-07-29
TW201400115A (zh) 2014-01-01
EA201401082A1 (ru) 2015-03-31
EP3524230A1 (en) 2019-08-14
EP3970693B1 (en) 2025-07-02
ES2715844T3 (es) 2019-06-06
IN2014DN07082A (enExample) 2015-04-10
BR112014024479A8 (pt) 2017-10-10
SMT201900121T1 (it) 2019-02-28
CL2014002524A1 (es) 2015-01-23
US10213421B2 (en) 2019-02-26
JP2015512433A (ja) 2015-04-27
UY34730A (es) 2013-10-31
HUE041519T2 (hu) 2019-05-28
HUE056943T2 (hu) 2022-04-28
JP6700332B2 (ja) 2020-05-27
ES3044310T3 (en) 2025-11-26
US20200253950A1 (en) 2020-08-13
US11612596B2 (en) 2023-03-28
CN104203213A (zh) 2014-12-10
AR090596A1 (es) 2014-11-26
AU2013245028B2 (en) 2017-04-20
LT2833864T (lt) 2019-03-12
KR20200105676A (ko) 2020-09-08
HRP20190069T1 (hr) 2019-04-05
PL3524230T3 (pl) 2022-01-10
PT2833864T (pt) 2019-03-28
CY1121137T1 (el) 2020-05-29
JP2022081524A (ja) 2022-05-31
MX2014011787A (es) 2014-12-05
EP3524230B1 (en) 2021-08-11
TR201821285T4 (tr) 2019-01-21
DK2833864T3 (en) 2019-02-18
RS58360B1 (sr) 2019-03-29
BR112014024479A2 (enExample) 2017-06-20
EP3970693A1 (en) 2022-03-23
JP2018138557A (ja) 2018-09-06
EA027627B1 (ru) 2017-08-31
US20190151300A1 (en) 2019-05-23
PL2833864T3 (pl) 2019-05-31
ES2898179T3 (es) 2022-03-04
EP2833864A1 (en) 2015-02-11
SI2833864T1 (sl) 2019-03-29
WO2013149987A1 (en) 2013-10-10
DK3524230T3 (da) 2021-11-15
PH12014502241A1 (en) 2014-12-15
CA2869058A1 (en) 2013-10-10
MX358307B (es) 2018-08-14

Similar Documents

Publication Publication Date Title
NZ628993A (en) Pharmaceutical formulations comprising ccr3 antagonists
HRP20231037T1 (hr) Deuterirani spojevi za upotrebu u liječenju raka
TN2013000293A1 (en) Derivatives of azaindazole or diazaindazole type as medicament
MX2009008935A (es) Moduladores de las propiedades farmacocineticas de productos terapeuticos.
JO3271B1 (ar) مشتقات الكوينولين المضادة للجراثيم
JP2015038135A5 (enExample)
PH12015501945B1 (en) Formulations of organic compounds
NZ600231A (en) Pharmaceutical compositions comprising sigma receptor ligands
PH12015502802A1 (en) Formulation comprising a hypolipidemic agent
MX394588B (es) Composición farmacéutica.
WO2009140341A3 (en) Atorvastatin compositions
AR100977A1 (es) Formulación compuesta para la administración oral que comprende ezetimiba y rosuvastatina, y un proceso para su preparación
UA101305C2 (ru) Антибактериальные производные хинолина
MY206262A (en) Macrocyclic tyrosine kinase inhibitor and uses thereof
JO2725B1 (en) Quinoline antibacterial derivatives
EA201991286A1 (ru) Твердая фармацевтическая композиция для перорального применения, содержащая тенофовир и эмтрицитабин
MX2009008176A (es) Derivados de tetrahidro-naftaleno sustituidos con heterociclos, su preparacion y su uso como medicamentos.
HRP20151340T1 (hr) Derivati tieno[2,3-d] pirimidina i njihova primjena u lijeäśenju aritmije
WO2010137040A3 (en) Novel pharmaceutical compositions of ranolazine
NZ764004A (en) Heteroaryl compounds as muscarinic m1 receptor positive allosteric modulators
JO2685B1 (en) Quinoline antibacterial derivatives
JO2970B1 (en) Quinoline antibacterial derivatives
MX2009012933A (es) Derivados de ariloxazol ariloxadiazol y bencimidazol como moduladores de la actividad del receptor de somatostatinas.
JO2683B1 (en) Quinoline antibacterial derivatives
MX2010011767A (es) Derivados de benzocicloheptano y benzoxepina.

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 APR 2018 BY CPA GLOBAL

Effective date: 20170318

ASS Change of ownership

Owner name: ALKAHEST, INC., US

Effective date: 20170918

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 APR 2019 BY CPA GLOBAL

Effective date: 20180309

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 APR 2020 BY CPA GLOBAL

Effective date: 20190314

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 APR 2021 BY CPA GLOBAL

Effective date: 20200227

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 APR 2022 BY CPA GLOBAL

Effective date: 20210312

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 APR 2023 BY CPA GLOBAL

Effective date: 20220310

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 APR 2024 BY CPA GLOBAL

Effective date: 20230309

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 APR 2025 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS

Effective date: 20240314

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 APR 2026 BY COMPUTER PACKAGES INC

Effective date: 20250317